DDInter1335 DDInter1819
Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy, or a CAR-T cell therapy for B-cell acute lymphoblastic leukemia. It was granted approval by FDA in August 2017 under the market name Kymriah. Tisagenlecleucel is an immunocellular therapy that involves autologous T cells that are collected from each individual patient and genetically engineered to express a specific protein called a chimeric antigen receptor (CAR) that specifically target CD19 antigens. Modified T cells are infused back into the patient's body. These CD19-directed chimeric antigen receptors (CD19 CAR-T cells) direct the T cells to target and kill leukemia cells that express CD19 on the cell surface. In a multicenter clinical trial involving pediatric and young adult patients with relapsed or refractory B-cell precursor ALL, the overall remission rate within three months of treatment was 83 percent.
Omacetaxine mepesuccinate {u} (Compound) binds {v} (Gene) RPL3
Omacetaxine mepesuccinate {u} (Compound) upregulates {v} (Gene) DUSP8
Omacetaxine mepesuccinate {u} (Compound) downregulates {v} (Gene) B4GAT1
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rituximab
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Risankizumab
Omacetaxine mepesuccinate {u} may lead to a major life threatening interaction when taken with {v} Indomethacin
Omacetaxine mepesuccinate {u} may lead to a major life threatening interaction when taken with {v} Avapritinib
Omacetaxine mepesuccinate (Compound) binds RPL3 (Gene)
Omacetaxine mepesuccinate (Compound) upregulates DUSP8 (Gene)
Omacetaxine mepesuccinate (Compound) downregulates B4GAT1 (Gene)
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Rituximab
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Risankizumab
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Indomethacin
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Avapritinib